Msi-H colorectal cancer
Clinical trials for Msi-H colorectal cancer explained in plain language.
Never miss a new study
Get alerted when new Msi-H colorectal cancer trials appear
Sign up with your email to follow new studies for Msi-H colorectal cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a new nucleotide analogue boost cancer treatment?
Disease control Stopped earlyThis trial is testing an experimental drug called NUC-3373, a nucleotide analogue, in combination with standard cancer drugs for people with advanced solid tumors. The study has two parts: one combining NUC-3373 with pembrolizumab, and the other combining it with docetaxel. The g…
Matched conditions: MSI-H COLORECTAL CANCER
Phase 1/2 • Sponsor: NuCana plc • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Colon cancer combo trial ends early – only one patient enrolled
Disease control Stopped earlyThis study tested a combination of two drugs (regorafenib and pembrolizumab) for people with a specific type of advanced colorectal cancer called MSI-H. The goal was to see if the combination worked better than pembrolizumab alone. The trial was stopped early after enrolling only…
Matched conditions: MSI-H COLORECTAL CANCER
Phase 2 • Sponsor: Anwaar Saeed • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC